🇺🇸 FDA
Pipeline program

Byooviz 10 mg/ml solution for injection

SB11-2002

Phase 2 small_molecule active

Quick answer

Byooviz 10 mg/ml solution for injection for Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV) is a Phase 2 program (small_molecule) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Samsung Bioepis NL B.V.
Indication
Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials